January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. https://doi.org/10.1161/CIR.0000000000000665.

Article  PubMed  Google Scholar 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.

CAS  Article  PubMed  Google Scholar 

de Souza Lima Bitar Y, Neto MG, JAL F, Pereira LV, KSO T, Akrami KM, et al. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis. Drugs R D. 2019;19:117–26.

Article  Google Scholar 

Ingrasciotta Y, Crisafulli S, Pizzimenti V, Marcianò I, Mancuso A, Andò G, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018;14(10):1057–69. https://doi.org/10.1080/17425255.2018.1530213.

CAS  Article  PubMed  Google Scholar 

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907.

CAS  Article  PubMed  Google Scholar 

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in Nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.

CAS  Article  PubMed  Google Scholar 

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.

CAS  Article  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.

CAS  Article  PubMed  Google Scholar 

Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13. https://doi.org/10.1111/jth.13323.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Eriksson BI, Dahl OE, Feuring M, Clemens A, Noack H, Hantel S, et al. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res. 2012;130(5):818–20. https://doi.org/10.1016/j.thromres.2012.07.004.

CAS  Article  PubMed  Google Scholar 

Patil T, Lebrecht M. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. Thromb Res. 2020;192:124–30. https://doi.org/10.1016/j.thromres.2020.04.015.

CAS  Article  PubMed  Google Scholar 

Kushnir M, Choi Y, Eisenberg R, Rao D, Tolu S, Gao J, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-Centre, retrospective analysis of chart data. Lancet Haematol. 2019;6(7):e359–65. https://doi.org/10.1016/S2352-3026(19)30086-9.

Article  PubMed  Google Scholar 

Deitelzweig S, Sah J, Kang A, Russ C, Preib M, Dhamane AD, et al. Effectiveness and safety of Apixaban versus warfarin in obese patients with Nonvalvular atrial fibrillation enrolled in Medicare and veteran affairs. Am J Cardiol. 2022;163:43–9. https://doi.org/10.1016/j.amjcard.2021.09.047.

CAS  Article  PubMed  Google Scholar 

Kido K, Ngorsuraches S. Comparing the efficacy and safety of direct Oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2019;53(2):165–70. https://doi.org/10.1177/1060028018796604.

CAS  Article  PubMed  Google Scholar 

Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, et al. Efficacy and safety of Apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation. 2019;139(20):2292–300. https://doi.org/10.1161/CIRCULATIONAHA.118.037955.

CAS  Article  PubMed  Google Scholar 

Mhanna M, Beran A, Al-Abdouh A, Sajdeya O, Abdulsattar W, Srour O, et al. Direct Oral anticoagulants versus warfarin in morbidly obese patients with Nonvalvular atrial fibrillation: a systematic review and Meta-analysis. Am J Ther. 2021;28(5):e531–9. https://doi.org/10.1097/MJT.0000000000001403.

Article  PubMed  Google Scholar 

Thangjui S, Kewcharoen J, Yodsuwan R, Trongtorsak A, Thyagaturu H, Shrestha B, et al. Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2021:pvab026. https://doi.org/10.1093/ehjcvp/pvab026. Epub ahead of print. PMID: 33730164.

Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. Plos One. 2018;13:e0191722.

Article  Google Scholar 

ClinicalTrails.gov. Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib. In VA Patients With Medicare. [cited 2022 Jan 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT04681482

SCHULMAN S, KEARON C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.

CAS  Article  PubMed  Google Scholar 

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. https://doi.org/10.1111/jth.13140.

CAS  Article  PubMed  Google Scholar 

Wiethorn EE, Bell CM, Wiggins BS. Effectiveness and safety of direct Oral anticoagulants in patients with Nonvalvular atrial fibrillation and weighing ≥ 120 kilograms versus 60–120 kilograms. Am J Cardiovasc Drugs. 2021;21(5):545–51. https://doi.org/10.1007/s40256-021-00470-0.

CAS  Article  PubMed  Google Scholar 

Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res. 2017;113(9):1074–86. https://doi.org/10.1093/cvr/cvx106.

CAS  Article  PubMed  Google Scholar 

Antonopoulos AS, Oikonomou EK, Antoniades C, Tousoulis D. From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. Obes Rev. 2016;17(10):989–1000. https://doi.org/10.1111/obr.12440.

CAS  Article  PubMed  Google Scholar 

Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39(4):578–84. https://doi.org/10.1016/S0735-1097(01)01802-2.

Article  PubMed  Google Scholar 

Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a Meta-analysis. PLoS One. 2012;7(8):e43892. https://doi.org/10.1371/journal.pone.0043892.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43(8):1439–44. https://doi.org/10.1016/j.jacc.2003.11.039.

Article  PubMed  Google Scholar 

Wang L, Liu W, He X, Chen Y, Lu J, Liu K, et al. Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. Int J Obes. 2016;40(2):220–8. https://doi.org/10.1038/ijo.2015.176.

CAS  Article  Google Scholar 

Ward C, Conner G, Donnan G, Gallus A, McRae S. Practical management of patients on apixaban: a consensus guide. Thromb J. 2013;11(1):27. https://doi.org/10.1186/1477-9560-11-27.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kido K, Lee JC, Hellwig T, Gulseth MP. Use of direct Oral anticoagulants in morbidly obese patients. Pharmacotherapy. 2020;40(1):72–83. https://doi.org/10.1002/phar.2353.

Article  PubMed  Google Scholar 

Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908–16. https://doi.org/10.1111/bcp.12114.

CAS  Article  PubMed  PubMed Central  Google Scholar